联合用药治疗中重度高血压疗效观察

目的评价缬沙坦和氢氯噻嗪联合治疗中/重度高血压的临床价值。方法中/重度高血压病人100例,随机分成2组。观察组每日晨起服用缬沙坦80mg/次,氢氯噻嗪12.5～25mg/次;对照组每日晨起服用缬沙坦80mg/次,疗程为8周。疗效判定:显效:舒张压下降≥1.3kPa并且降至正常,或下降≥2.6kPa,收缩压降至正常;有效:虽然舒张压下降<1.3kPa,但已降至正常,或下降1.3～2.52kPa,收缩压下降≥3.9kPa;无效:血压下降未达上述标准。结果观察组显效率72%,对照组显效率50%,两组差异有显著性;观察组总有效率92%,对照组总有效率72%,两组差异有显著性。结论缬沙坦和氢氯噻嗪联合治疗中重度高血压的临床疗效,明显优于缬沙坦单一用药。

Curative Observation of Treatment on Middle-heavy Hypertension with Valsartan and Hydrochlorothiazide

Objective To assess the curative Value of Treatment on middle - heavy Hypertension with Valsartan and Hydrochlomthiazide.Methods 50 cases of middle- heavy Hypertension with Valsartan 80 nag 13o qd and Hydmehlomthiazide 12.5 ～ 25 mg po qd, for 8weeks; Control group, 50 eases of middle - heavy Hypertension with Valsartan 80mg po qd, for 8weeks; Observed blood pressure.Results The tolal effective rate was 92% in observe group and 72% in control group. Conclusion Treatment on middle - heavy Hypertension with Valsartan and Hydrochlomthiazide might be better than with Valsartan.